dexelvucitabine: Clinical Trials

11 trials of dexelvucitabine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 4 terminated. 9 Phase 2, 2 Phase 1, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 29Completed 6, Terminated 3
Phase 12Completed 2
Not applicable1Terminated 1

Follow dexelvucitabine: new trials by email Literature Review of dexelvucitabine trials Research Report on dexelvucitabine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
Elvucitabine - HIV Infections
Phase 2CompletedAlexion Pharmaceuticals, Inc.72008-05-012023-08-14
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
Elvucitabine, Lamivudine, Emtricitabine - Human Immunodeficiency Virus (HIV)-1 Infection
Phase 2CompletedAlexion Pharmaceuticals, Inc.42006-09-012023-08-14
Safety Study of Elvucitabine in HIV-1 Subjects
elvucitabine - HIV Infections
Phase 2CompletedThomas Jefferson University52006-09-012009-02-04
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
Elvucitabine, Lamivudine, Tenofovir - HIV Infections
Phase 2CompletedAlexion Pharmaceuticals, Inc.762006-05-012023-08-30
Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs
Dexelvucitabine - HIV Infections, Human Immunodeficiency Virus
Phase 2TerminatedIncyte Corporation2502006-04-012018-08-23
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
Elvucitabine, Lamivudine - HIV Infections
Phase 1 / Phase 2CompletedAlexion Pharmaceuticals, Inc.202006-03-312023-08-25
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
ACH126, 433 - Chronic Hepatitis B
Phase 2TerminatedAlexion Pharmaceuticals, Inc.852002-07-012021-02-18
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
ACH-126,443, Lamivudine, Placebo - Hepatitis B, Chronic
Phase 2CompletedAlexion Pharmaceuticals, Inc.792002-02-012021-02-18
A Study of DPC 817 in HIV-Infected Males
DPC 817 - HIV Infections
Phase 1CompletedPharmasset302005-07-19
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.
ACH126-443 (Beta-L-Fd4C) - HIV Infections
Phase 2TerminatedAlexion Pharmaceuticals, Inc.602015-12-30
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
ACH-126, 443 (beta-L-Fd4C) - Chronic Hepatitis B
Not applicableTerminatedAlexion Pharmaceuticals, Inc.1002009-08-19

Conditions studied

HIV Infections (7)  ·  Hepatitis B, Chronic (3)  ·  Acquired Immunodeficiency Syndrome (2)

Sponsors

Alexion Pharmaceuticals, Inc. (8)  ·  Incyte Corporation (1)  ·  Pharmasset (1)  ·  Thomas Jefferson University (1)

Countries

United States (9)  ·  Germany (2)  ·  Puerto Rico (2)  ·  Bulgaria (1)  ·  Canada (1)  ·  China (1)  ·  Dominican Republic (1)  ·  Federal Republic of Yugoslavia (1)  ·  Spain (1)

Top investigators

Kathleen Squires, MD (1)